Top Tweets for #digithf
Predicted by previous simulations by statistical🧙♂️#BrianClaggett @CircAHA
Recurrent-event methods provided lesser power than time-to-first in scenarios where drug discontinuation approaches ≥60%
#DIGITHF drug discontinuation:
57% (digitoxin), 54% (PBO)
https://t.co/su51NG7eoO
#EndpointSelection is always a gamble
#DIGITHF: recurrent event analyses performed worse than first events (driven by v high drug discontinuation)
..despite double # of events!
1°:☠️+first 🏥 (N=506): 0.82(0.69-0.98)
2°:☠️+total🏥(N=1068): 0.85(0.67-1.09)
h/t @Kieranfdocherty
Hoy recomendamos la lectura de este editorial sobre los 5 puntos clave del ensayo #DIGITHF
🧲Un mensaje claro: la seguridad de los glucósidos cardíacos. Los indicios de daño de otros estudios se debían a sesgos. ✔️Aleatorización =no hay daño
#digitoxina NO es igual que #digoxina
Darn it. There’s no editorial. Why? Because the heart failure community is stunned. They are speechless. No worries.
You can read this (slightly biased) editorial for free on @theheartorg
https://t.co/0SuYQSvcJ3
#esccongress #esc2025
#DIGITHF "A Renaissance for Cardiac Glycosides"
Bravo @JBauersachsMD👏🏾
Shape of KM curve reflecting:
- Long enrollment '15-'23 (all curves converge eventually!)
- High risk cohort (NYHA III/IV)
- High study drug discontinuation (~55%)
- Few pts studied beyond 5y
#ESCCongress
#DigitHF demonstrated an 18% reduction in death & HHF with digitoxin vs placebo on top of GDMT in only 1212 patients w advanced HFrEF (36 mo)!
Efficacy driven by 📉 in ☠️ + 🏥
What is #digitoxin & how does the evidence fit into current Tx? Listen @radcliffeCARDIO
#ESCCongress
🎙️NEW #ESCCongress 2025 🔥 Hot Line Discussion 🌟 Prof Udo Bavendiek joins host Dr @hvanspall to explore findings from the DIGIT-HF trial.
📽️Watch here 👉 https://t.co/XjpjH35s1g
📊Digitoxin reduced the risk of all-cause mortality and hospitalisation in patients with worsening heart failure.
#ESCCongress2025 #ESC2025 #CardioEd
🔬 #ESC2025 | Estudio DIGIT-HF
¿Puede la digitoxina mejorar el pronóstico en insuficiencia cardíaca con fracción de eyección reducida (ICFEr)?
🩺 Por el Dr. @tupayachi_omar
🔗 https://t.co/2XDC4ykAyl
#ESC2025 #DIGITHF #Farmacologia #Digitoxina #Cardiología
Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8mpwOpVo7U
#ESCCongress | @escardio
Effect of GDMT on ACM and CVD/HF Hosp in relation to baseline risk, now including #VICTOR and #DIGITHF #ESCCongress2025. What is your take on these trials in perspective of landmark #HFrEF RCTs ?
DIGIT-HF Trial‼️Análisis @EmmanuelScatu
multicéntrico, aleatorizado, doble ciego (Alemania, Austria, Serbia)
ICFEr sintomática.
⚖️ Intervención:Digitoxina vs placebo + tratamiento estándar.
🎯 Objetivo: muerte por cualquier causa + internación por IC.
RESULTADOS 36 (meses)
Started #ESCCongress with a bang ❗️
I still can’t get over how many potentially practice changing #LBCT are being released here! This was just the first one!
My favorite will have to be #DIGITHF and the potential so a drug that is inexpensive to be used with more confidence that we are doing more than just potentially improving symptoms.
So we are now “back to the future” with digitoxin!#DIGITHF #LBCT #ESCCongress
♥️ safe, easy titration, a bit sicker patients, well treated pts
❌No reduction in 🏥, underpowered and small study
Positive trial: Will it change your clinical practice? It will for me! Let’s see where the guidelines go!
Not the best example of: “What doesn’t kill you makes you stronger.”
If you consider digitoxin for your patient, it’s reasonable to prescribe it.
If you don’t, everything will probably still be fine.
Congratulations to the team. We need these RCTs!
#DIGITHF
#ESCcongress
#HOTLINE #LBCT #ESCCongress #DIGITHF
DIGIT-HF: Digitoxin in Patients with Heart Failure & Reduced Ejection Fraction
🫀DIG trial from many years ago showed no diff in mortality but better CV mortality with digoxin (but dig >1 assoc with worse outcomes)- no trials since!
🫀trial of HFeEF (EF<\=30%), 1250 pts, Dig 0.07mg 🆚 placebo: 20% female,70% class3/4 HF, <20% on SGLT2i
🫀18% ⬇️ in primary endpoint, including significant ⬇️ all-cause mortality in Dig Tx arm vs placebo
🫀No diff in adverse events
📎 @nejm https://t.co/op5T2V44UO
Back to the Future at #HeartFailure2025
Revisiting the contemporary role of digoxin in #HFrEF
Guidelines have serially downgraded its recommendation & use globally has declined
Will #DIGITHF (n=1212 pts) be sufficiently powered to change practice?
https://t.co/YBXB7qUXHC
HERMES Investigator Meeting in Baveno, Italy
Will IL-6 inhibition with ziltivekimab improve outcome in #HFpEF?
We will find out in a 2027.
👥Target n=5600
🌍46 countries
https://t.co/YyLYjkfGuZ
@manesh_patelMD Great points all around regarding indication bias issues.
Two modest-size trials are underway (#DIGITHF & #DECISION) evaluating digitoxin/digoxin in HF in contemporary era. Neither specifically exclude AF, and #DIGITHF stratifies by AF status.
Last Seen Hashtags on Sotwe
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
240.2M followers
Barack Obama
@barackobama
119.3M followers
Donald J. Trump
@realdonaldtrump
111.6M followers
Cristiano Ronaldo
@cristiano
109.3M followers
Narendra Modi
@narendramodi
106.9M followers
Rihanna
@rihanna
97.4M followers
NASA
@nasa
92.1M followers
Justin Bieber
@justinbieber
90.6M followers
KATY PERRY
@katyperry
87M followers
Taylor Swift
@taylorswift13
80.8M followers
Lady Gaga
@ladygaga
72.4M followers
Kim Kardashian
@kimkardashian
69.5M followers
Virat Kohli
@imvkohli
68.9M followers
YouTube
@youtube
68.6M followers
Bill Gates
@billgates
63.5M followers
The Ellen Show
@theellenshow
62.5M followers
CNN
@cnn
61.9M followers
Neymar Jr
@neymarjr
61.5M followers
X
@x
60.9M followers
Selena Gomez
@selenagomez
60.1M followers